Spinal Muscular Atrophy Treatment Market Size, Top Share Forecast to 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Spinal Muscular Atrophy Treatment Market Size Analysis

Global Spinal Muscular Atrophy Treatment Market Introduction
By SMA Type
1. Introduction
  1. SMA Type By Value
2. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
  1. By Value
3. Intermediate (type II or chronic SMA)
  1. By Value
4. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
  1. By Value
5. Type IV (adult SMA)
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Gene Therapy
  1. By Value
3. Drugs
  1. By Value
4. Medication
  1. By Value
5. Physical Therapy
  1. By Value
6. Surgery
  1. By Value
7. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Intrathecal
  1. By Value
4. Paranteral
  1. By Value
By Drug
1. Introduction
  1. Drug By Value
2. Nusinersen
  1. By Value
3. Onasemnogene
  1. By Value
4. Abeparvovec
  1. By Value
5. Others
  1. By Value
By Administration
1. Introduction
  1. Administration By Value
2. Intrathecal
  1. By Value
3. Intraspinal
  1. By Value
4. Subcutaneous
  1. By Value
5. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Online Pharmacy
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Homecare
  1. By Value
4. Specialty Clinics
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By SMA Type
1. Introduction
  1. SMA Type By Value
2. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
  1. By Value
3. Intermediate (type II or chronic SMA)
  1. By Value
4. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
  1. By Value
5. Type IV (adult SMA)
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Gene Therapy
  1. By Value
3. Drugs
  1. By Value
4. Medication
  1. By Value
5. Physical Therapy
  1. By Value
6. Surgery
  1. By Value
7. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Intrathecal
  1. By Value
4. Paranteral
  1. By Value
By Drug
1. Introduction
  1. Drug By Value
2. Nusinersen
  1. By Value
3. Onasemnogene
  1. By Value
4. Abeparvovec
  1. By Value
5. Others
  1. By Value
By Administration
1. Introduction
  1. Administration By Value
2. Intrathecal
  1. By Value
3. Intraspinal
  1. By Value
4. Subcutaneous
  1. By Value
5. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Online Pharmacy
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Homecare
  1. By Value
4. Specialty Clinics
  1. By Value
5. Others
  1. By Value
U.S.
1. By SMA Type
  1. Introduction
    1. SMA Type By Value
  2. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
    1. By Value
  3. Intermediate (type II or chronic SMA)
    1. By Value
  4. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
    1. By Value
  5. Type IV (adult SMA)
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Gene Therapy
    1. By Value
  3. Drugs
    1. By Value
  4. Medication
    1. By Value
  5. Physical Therapy
    1. By Value
  6. Surgery
    1. By Value
  7. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Intrathecal
    1. By Value
  4. Paranteral
    1. By Value
4. By Drug
  1. Introduction
    1. Drug By Value
  2. Nusinersen
    1. By Value
  3. Onasemnogene
    1. By Value
  4. Abeparvovec
    1. By Value
  5. Others
    1. By Value
5. By Administration
  1. Introduction
    1. Administration By Value
  2. Intrathecal
    1. By Value
  3. Intraspinal
    1. By Value
  4. Subcutaneous
    1. By Value
  5. Others
    1. By Value
6. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Pharmacy
    1. By Value
7. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Homecare
    1. By Value
  4. Specialty Clinics
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By SMA Type
1. Introduction
  1. SMA Type By Value
2. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
  1. By Value
3. Intermediate (type II or chronic SMA)
  1. By Value
4. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
  1. By Value
5. Type IV (adult SMA)
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Gene Therapy
  1. By Value
3. Drugs
  1. By Value
4. Medication
  1. By Value
5. Physical Therapy
  1. By Value
6. Surgery
  1. By Value
7. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Intrathecal
  1. By Value
4. Paranteral
  1. By Value
By Drug
1. Introduction
  1. Drug By Value
2. Nusinersen
  1. By Value
3. Onasemnogene
  1. By Value
4. Abeparvovec
  1. By Value
5. Others
  1. By Value
By Administration
1. Introduction
  1. Administration By Value
2. Intrathecal
  1. By Value
3. Intraspinal
  1. By Value
4. Subcutaneous
  1. By Value
5. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Online Pharmacy
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Homecare
  1. By Value
4. Specialty Clinics
  1. By Value
5. Others
  1. By Value
U.K.
1. By SMA Type
  1. Introduction
    1. SMA Type By Value
  2. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
    1. By Value
  3. Intermediate (type II or chronic SMA)
    1. By Value
  4. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
    1. By Value
  5. Type IV (adult SMA)
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Gene Therapy
    1. By Value
  3. Drugs
    1. By Value
  4. Medication
    1. By Value
  5. Physical Therapy
    1. By Value
  6. Surgery
    1. By Value
  7. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Intrathecal
    1. By Value
  4. Paranteral
    1. By Value
4. By Drug
  1. Introduction
    1. Drug By Value
  2. Nusinersen
    1. By Value
  3. Onasemnogene
    1. By Value
  4. Abeparvovec
    1. By Value
  5. Others
    1. By Value
5. By Administration
  1. Introduction
    1. Administration By Value
  2. Intrathecal
    1. By Value
  3. Intraspinal
    1. By Value
  4. Subcutaneous
    1. By Value
  5. Others
    1. By Value
6. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Pharmacy
    1. By Value
7. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Homecare
    1. By Value
  4. Specialty Clinics
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By SMA Type
1. Introduction
  1. SMA Type By Value
2. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
  1. By Value
3. Intermediate (type II or chronic SMA)
  1. By Value
4. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
  1. By Value
5. Type IV (adult SMA)
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Gene Therapy
  1. By Value
3. Drugs
  1. By Value
4. Medication
  1. By Value
5. Physical Therapy
  1. By Value
6. Surgery
  1. By Value
7. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Intrathecal
  1. By Value
4. Paranteral
  1. By Value
By Drug
1. Introduction
  1. Drug By Value
2. Nusinersen
  1. By Value
3. Onasemnogene
  1. By Value
4. Abeparvovec
  1. By Value
5. Others
  1. By Value
By Administration
1. Introduction
  1. Administration By Value
2. Intrathecal
  1. By Value
3. Intraspinal
  1. By Value
4. Subcutaneous
  1. By Value
5. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Online Pharmacy
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Homecare
  1. By Value
4. Specialty Clinics
  1. By Value
5. Others
  1. By Value
China
1. By SMA Type
  1. Introduction
    1. SMA Type By Value
  2. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
    1. By Value
  3. Intermediate (type II or chronic SMA)
    1. By Value
  4. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
    1. By Value
  5. Type IV (adult SMA)
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Gene Therapy
    1. By Value
  3. Drugs
    1. By Value
  4. Medication
    1. By Value
  5. Physical Therapy
    1. By Value
  6. Surgery
    1. By Value
  7. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Intrathecal
    1. By Value
  4. Paranteral
    1. By Value
4. By Drug
  1. Introduction
    1. Drug By Value
  2. Nusinersen
    1. By Value
  3. Onasemnogene
    1. By Value
  4. Abeparvovec
    1. By Value
  5. Others
    1. By Value
5. By Administration
  1. Introduction
    1. Administration By Value
  2. Intrathecal
    1. By Value
  3. Intraspinal
    1. By Value
  4. Subcutaneous
    1. By Value
  5. Others
    1. By Value
6. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Pharmacy
    1. By Value
7. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Homecare
    1. By Value
  4. Specialty Clinics
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By SMA Type
1. Introduction
  1. SMA Type By Value
2. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
  1. By Value
3. Intermediate (type II or chronic SMA)
  1. By Value
4. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
  1. By Value
5. Type IV (adult SMA)
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Gene Therapy
  1. By Value
3. Drugs
  1. By Value
4. Medication
  1. By Value
5. Physical Therapy
  1. By Value
6. Surgery
  1. By Value
7. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Intrathecal
  1. By Value
4. Paranteral
  1. By Value
By Drug
1. Introduction
  1. Drug By Value
2. Nusinersen
  1. By Value
3. Onasemnogene
  1. By Value
4. Abeparvovec
  1. By Value
5. Others
  1. By Value
By Administration
1. Introduction
  1. Administration By Value
2. Intrathecal
  1. By Value
3. Intraspinal
  1. By Value
4. Subcutaneous
  1. By Value
5. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Online Pharmacy
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Homecare
  1. By Value
4. Specialty Clinics
  1. By Value
5. Others
  1. By Value
UAE
1. By SMA Type
  1. Introduction
    1. SMA Type By Value
  2. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
    1. By Value
  3. Intermediate (type II or chronic SMA)
    1. By Value
  4. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
    1. By Value
  5. Type IV (adult SMA)
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Gene Therapy
    1. By Value
  3. Drugs
    1. By Value
  4. Medication
    1. By Value
  5. Physical Therapy
    1. By Value
  6. Surgery
    1. By Value
  7. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Intrathecal
    1. By Value
  4. Paranteral
    1. By Value
4. By Drug
  1. Introduction
    1. Drug By Value
  2. Nusinersen
    1. By Value
  3. Onasemnogene
    1. By Value
  4. Abeparvovec
    1. By Value
  5. Others
    1. By Value
5. By Administration
  1. Introduction
    1. Administration By Value
  2. Intrathecal
    1. By Value
  3. Intraspinal
    1. By Value
  4. Subcutaneous
    1. By Value
  5. Others
    1. By Value
6. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Pharmacy
    1. By Value
7. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Homecare
    1. By Value
  4. Specialty Clinics
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By SMA Type
1. Introduction
  1. SMA Type By Value
2. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
  1. By Value
3. Intermediate (type II or chronic SMA)
  1. By Value
4. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
  1. By Value
5. Type IV (adult SMA)
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Gene Therapy
  1. By Value
3. Drugs
  1. By Value
4. Medication
  1. By Value
5. Physical Therapy
  1. By Value
6. Surgery
  1. By Value
7. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Intrathecal
  1. By Value
4. Paranteral
  1. By Value
By Drug
1. Introduction
  1. Drug By Value
2. Nusinersen
  1. By Value
3. Onasemnogene
  1. By Value
4. Abeparvovec
  1. By Value
5. Others
  1. By Value
By Administration
1. Introduction
  1. Administration By Value
2. Intrathecal
  1. By Value
3. Intraspinal
  1. By Value
4. Subcutaneous
  1. By Value
5. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Online Pharmacy
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Homecare
  1. By Value
4. Specialty Clinics
  1. By Value
5. Others
  1. By Value
Brazil
1. By SMA Type
  1. Introduction
    1. SMA Type By Value
  2. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
    1. By Value
  3. Intermediate (type II or chronic SMA)
    1. By Value
  4. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
    1. By Value
  5. Type IV (adult SMA)
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Gene Therapy
    1. By Value
  3. Drugs
    1. By Value
  4. Medication
    1. By Value
  5. Physical Therapy
    1. By Value
  6. Surgery
    1. By Value
  7. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Intrathecal
    1. By Value
  4. Paranteral
    1. By Value
4. By Drug
  1. Introduction
    1. Drug By Value
  2. Nusinersen
    1. By Value
  3. Onasemnogene
    1. By Value
  4. Abeparvovec
    1. By Value
  5. Others
    1. By Value
5. By Administration
  1. Introduction
    1. Administration By Value
  2. Intrathecal
    1. By Value
  3. Intraspinal
    1. By Value
  4. Subcutaneous
    1. By Value
  5. Others
    1. By Value
6. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Pharmacy
    1. By Value
7. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Homecare
    1. By Value
  4. Specialty Clinics
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Spinal Muscular Atrophy Treatment Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Pfizer Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Biogen Idec
Boehringer Ingelheim GmbH
Ionis Pharmaceuticals Inc.
Avexis Inc.
Novartis AG
Cytokinetics Inc.
Hoffmann-La Roche AG
Regeneron Pharmaceuticals Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment